CBC
Well-documented
Well-documented
Multiple authoritative sources agree on dosing and effects.
- 3 corroborating sources
- 2 ROAs with full dose ladders
- duration data present
- 16 combo interactions documented
- toxicity data (PsychonautWiki)
- dose data not in PW/TripSit (unverifiable)
- 3 corroborating sources
- 2 ROAs with full dose ladders
- duration data present
- 16 combo interactions documented
- toxicity data (PsychonautWiki)
- dose data not in PW/TripSit (unverifiable)
Summary
CBC is a rare, non-intoxicating cannabinoid found in small amounts in Cannabis sativa. It shows preferential affinity for CB2 receptors, TRPA1, TRPV1, and other TRP channels, demonstrating anti-inflammatory, analgesic, anticonvulsant, antidepressant-like, and neuroprotective properties in preclinical studies. Human data are sparse; most information derives from animal studies and anecdotal reports with commercial CBC isolates.
Dose Information
Dose basis. Ranges compiled from commercial CBC isolate labels and user reports; no controlled human titration studies exist. Interindividual variability likely high; treat as provisional and titrate cautiously. Ranges inferred from user reports and typical fill strengths; delivered mg per puff varies with device temperature and puff duration. Start at the low end to assess airway sensitivity due to TRPA1 agonism of CBC. (Dose figures and this note are from Drugs.Wiki.)
| ROA | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| Oral | 10-30mg | 30-70mg | 70-150mg | 150mg+ |
| Vaporized | 1-5mg | 5-20mg | 20-50mg | 50mg+ |
Onset, Duration & After-effects
| ROA | Onset | Comeup | Peak | Offset | Total |
|---|---|---|---|---|---|
| Oral | 30-90 min | 30-60 min | 1-3 hrs | 2-4 hrs | 4-9.5 hrs |
| Vaporized | 0-5 min | 5-15 min | 10-30 min | 30-60 min | 0.75-1.83 hrs |
Add to PsychonautWiki Journal
The PsychonautWiki Journal logging app doesn't include every substance. To track CBC there, start adding an ingestion, search for the name, and choose to add it as a custom substance. Paste these values:
CBC Source: SubstanceSearch (substancesearch.com) Oral dose (mg): threshold 5 · light 10-30 · common 30-70 · strong 70-150 · heavy 150+ Vaporized dose (mg): threshold 1 · light 1-5 · common 5-20 · strong 20-50 · heavy 50+ Oral duration: onset 0.5-1.5h · come-up 0.5-1h · peak 1-3h · offset 2-4h · total 4-9.5h · after-effects 2-12h Vaporized duration: onset 0-5m · come-up 5-15m · peak 10-30m · offset 0.5-1h · total 0.75-1.83h · after-effects 2-12h Note: ranges are harm-reduction guidance, not a prescription. Start low, go slow, and test your substances.
Tip: for quicker logging you can also add a Custom Unit in the app, e.g. common dose ~ 50 mg (Oral).
The app keeps custom substances simple, so the full dose ranges live in the description text above. Ranges are harm-reduction guidance, not a prescription.
Tolerance
Tolerance Decay
Acute tolerance: develops within a single session — the reset numbers above apply after sustained heavy use, not after one binge. Within-session tachyphylaxis usually resets largely overnight.
No controlled human data. Tolerance, if any, appears to build slowly with daily use and decays over weeks, extrapolated from general cannabinoid exposure patterns and user reports.
Cross-Tolerances
Effects
- Anxiolysis
- Body relaxation
- Pain relief
- Anti-inflammatory relief
- Stimulation
- Increased heart rate
- Nausea
- Headaches
- Headache
- Sedation
- Clear-headed focus
- Mild mood lift
- Reduced anxiety
- Wakefulness
- Motivation enhancement
- Focus enhancement
- Memory enhancement
- Anxiety suppression
- Cognitive euphoria
- Anxiety
- Increased libido
- Increased music appreciation
- Color enhancement
- Light sensitivity
- Appetite suppression
- Dehydration
- Dulled perception
- Spontaneous physical sensations
Combinations
Cross-Check CBC with another substanceHelpful Links
Report an issue or suggest an edit
Spotted incorrect or dangerous information, have a correction, a new study, or a useful addition for CBC? Let us know. Reports are reviewed by moderators — this is not posted publicly.